Trial Profile
Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Irinotecan
- Indications Oesophageal cancer
- Focus Adverse reactions
- 16 Mar 2021 Status changed from recruiting to completed.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.